AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01568411
Drug: TD-1211
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1
Trial: NCT01568411
Drug: TD-1211+ itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 2
Trial: NCT00667277
Drug: bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
Trial: NCT01158612
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of Growth hormone in the patella tendon.
Trial: NCT04238845
Drug: AQSP Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three days treatment of all children with AQSP for SMC
Trial: NCT00624338
Drug: Atacicept 75 mg
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Trial: NCT00624338
Drug: Atacicept 150 mg
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Trial: NCT01548638
Drug: Galantamine ER
RxNorm normalized name: galantamine Extended Release Oral Capsule
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER.
Trial: NCT00938548
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 75 mg orally
Trial: NCT00938548
Drug: Vitamin Complex (placebo)
RxNorm normalized name: vitamin B complex
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin Complex orally
Trial: NCT00499265
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
Trial: NCT00049764
Drug: Drotrecogin alfa (activated)
RxNorm normalized name: DROTRECOGIN ALFA (ACTIVATED)
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230763
Drug: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: in the evening during 84 days
Trial: NCT04856761
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
Trial: NCT02680067
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
Trial: NCT01926886
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
Trial: NCT01904487
Drug: Tiagabine
RxNorm normalized name: Tiagabine
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
Trial: NCT01665638
Drug: Canagliflozin 300 mg
RxNorm normalized name: canagliflozin 300 MG
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Trial: NCT01665638
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
Trial: NCT01665638
Drug: C-peptide
RxNorm normalized name: C-peptide
DrugBank: C-peptide (DB16187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
Trial: NCT00002828
Drug: raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01739595
Drug: enclomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Enclomiphene (DB06735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, capsules, taken one time daily, for 3 months
Trial: NCT01468519
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin via continuous subcutaneous insulin infusion
Trial: NCT01468519
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin via multiple daily injections
Trial: NCT02509546
Drug: 8-Chloroadenosine
RxNorm normalized name: 8-Chloroadenosine
DrugBank: 8-Chloroadenosine (DB16075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02291341
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine Delayed-Release Capsules 60 mg
Trial: NCT03879590
Drug: Doxophylline
RxNorm normalized name: Doxophylline
DrugBank: Doxofylline (DB09273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Trial: NCT03879590
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Trial: NCT00653315
Drug: Tramadol APAP
RxNorm normalized name: acetaminophen / tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, 37.5mg/325mg, single dose
Trial: NCT00653315
Drug: Ultracet
RxNorm normalized name: Ultracet
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, 37.5mg/325mg
Trial: NCT01581411
Drug: Tissue Plasminogen Activator
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
Trial: NCT02952742
Drug: Black Cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital Nutrients Black Cohosh Extract
Trial: NCT05828940
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, over-encapsulated
Trial: NCT00003018
Drug: dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/dose, PO, Days 1-28 of 5 week cycle
Trial: NCT00003018
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
Trial: NCT01287117
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Trial: NCT01786018
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01786018
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01786018
Drug: Fludarabin
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786018
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below.
Trial: NCT01786018
Drug: ATG
RxNorm normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
Trial: NCT00003803
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003803
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02614846
Drug: Hetrombopag Olamine
RxNorm normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02942498
Drug: Vitamin C 10mg/Kg Vitamin E 10 mg/Kg
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02350543
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01954290
Drug: Conivaptan
RxNorm normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
Trial: NCT01954290
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
Trial: NCT02813538
Drug: Indocyanine green clearance
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
Trial: NCT00216008
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00216008
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02477098
Drug: preoperative 0.5% ropivacaine hydrochloride preoperative
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
Trial: NCT02477098
Drug: postoperative 0.5% Ropivacaine hydrochloride
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
Trial: NCT00919022
Drug: Cyproterone Acetate (Androcur, BAY94-8367)
RxNorm normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in regular clinical practice receiving Androcur according to local drug information
Trial: NCT01186653
Drug: budesonide / formoterol
RxNorm normalized name: budesonide / formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
Trial: NCT01186653
Drug: fluticasone/salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
Trial: NCT02819596
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02819596
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02333331
Drug: bimagrumab
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Trial: NCT02133937
Drug: gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of a high concentration liquid formulation
Trial: NCT02133937
Drug: gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of a lyophilized formulation
Trial: NCT00738738
Drug: PD-0332334
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
Trial: NCT02381158
Drug: Nebulized beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
Trial: NCT01655511
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg, solution, single dose
Trial: NCT01655511
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg, solution, single dose
Trial: NCT01655511
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
Trial: NCT01878565
Drug: GM-CSF control
RxNorm normalized name: axatilimab-csfr
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
Trial: NCT01521845
Drug: omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Trial: NCT01451515
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally (PO).
Trial: NCT01451515
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV).
Trial: NCT01451515
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01451515
Drug: PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intramuscularly (IM) or IV.
Trial: NCT01451515
Drug: Erwinia asparaginase
RxNorm normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
Trial: NCT01451515
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT.
Trial: NCT01451515
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO.
Trial: NCT01451515
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV.
Trial: NCT01451515
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV.
Trial: NCT01451515
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01563601
Drug: Obatoclax Mesylate, Carboplatine and Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles
Trial: NCT01563601
Drug: Carboplatin and Etoposide
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles
Trial: NCT03623750
Drug: EGFR-TK Inhibitor
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
Trial: NCT03918993
Drug: Tadalafil 5mg tablet
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-day 5 mg dose of tadalafil for 8 weeks
Trial: NCT01855555
Drug: sedation with propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported.
Trial: NCT03047005
Drug: NB medication (Naltrexone Bupropion combination)
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB medication
Trial: NCT02132390
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02132390
Drug: Toremifene
RxNorm normalized name: Toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04819828
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tamsulosin (0.4 mg/day) for eight weeks.
Trial: NCT03842709
Drug: Pramipexole Oral Tablet
RxNorm normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
Trial: NCT01023282
Drug: ACR325
RxNorm normalized name: ACR325
DrugBank: ACR325 (DB05196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Trial: NCT01939379
Drug: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01939379
Drug: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no